The hard part is already done: the expensive phase of a major undertaking is finished, and the company is now in the col
The model's full reasoning — Q1 2024 call → NOWe need to determine if management conveys that the heavy phase of a major undertaking is substantially done AND the collecting phase has begun but is early in the numbers, with reported results still reflecting the paying phase. Key points from transcript: - Luis Felipe: "We're probably at the bottom of the credit cycle" - refers to credit cycle, not a major undertaking. "we remain confident about IFS' outlook going forward as we monitor the macro conditions" - improvement depends on macro. - Michela: "cost of risk remains high at 4.7%... good news is that these levels are lower than the previous quarter and slightly better than our estimates." - that's about credit cycle, not a completed build. - Carlos Tori: "we have been able to hold our market share... we have had to be more aggressive on pricing" - that's about competition, not a completed heavy phase. - On investments: "the investment portfolio was impacted by non-recurring events and by mark-to-market and we expect a recovery over the year." - that's about market conditions. - They talk about digital transformation: "We're breaking down geographic barriers through 100% digital products... We continue to develop our analytical capabilities... This is our strategy" - but no indication that the heavy phase is done. - They mention Impulso MyPeru program: "we have been awarded more than $1,400 million soles, of which almost $1 billion have been already disbursed." - that's a government program, not their own undertaking. - They mention synergies: "Izipay flow coming to Interbank accounts grew around 40% year-over-year." - but no description of completed heavy phase. - On wealth management: "asset under management continue to consolidate growing 11.5% year-over-year." - not an undertaking. - They mention cost management: "tight management of costs" - not a heavy phase. - The question asks specifically about a major undertaking with heavy phase done and collecting phase beginning with lag in numbers. Management does not describe such a situation. They talk about macroeconomic recovery, credit cycle normalization, and market volatility. They mention non-recurring events but not as part of a completed build.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| HUYA | HUYA Inc. | Q4 2023 | 2024-03-19 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| DAL | Delta Air Lines, Inc. | Q2 2023 | 2023-07-13 | A |
| CURV | Torrid Holdings Inc. | Q2 2022 | 2022-09-07 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| HTLF | Heartland Financial USA, Inc. | Q3 2017 | 2017-10-30 | B+ |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ARCB | ArcBest Corporation | Q4 2016 | 2017-02-08 | C |
IONS · Q1 2017 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the collecting phase, with r...YES Management describes the heavy phase of the SPINRAZA program as concluded ("we concluded our costly Phase III program"), with R&D expenses now expected to decline as the company transitions to a multiproduct profitable organization. They note that Q1 marked the first full quarter of commercial revenues ($47 million), with royalties of 5.2 million reflecting the early stage of this new revenue stream, while the reported results still include substantial R&D revenue (102 million) and show profitability driven by the ongoing evolution toward sustained profitability. The commercial benefits are visibly beginning but remain early, with the numbers carrying the burden of the prior development effort.
PKOH · Q3 2022 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the phase where they collect...YES Management describes the restructuring of 14 global locations as "largely completed," with the cycle finished and no significant customer attrition. They are now pivoting to focus on the balance sheet and "harvesting some of the significant cash investments" made over the last couple of years, while noting that earnings are continuing to improve sequentially in Q4 despite inflation. The reported results show positive cash flow and improved metrics, but the harvest is described as beginning, with the $60 million working capital investment expected to convert over 12-18 months, indicating the collecting phase is early and the numbers still largely reflect the prior paying phase.
AKYA · Q2 2023 → YESThe question is about whether management conveys that the company has recently finished the expensive, uncertain, or heavy phase of a major undertaking and has now entered the collecting phase, with r...YES Management describes the first phase (2021–end of 2022) as having completed its core objectives: successful launch of Fusion, portfolio development, organizational expansion, and platform enhancements. They explicitly frame the second phase as now beginning, with the reported Q2 results still carrying the burden of that prior heavy investment (high OpEx, RIF charges, gross-margin pressure) while the new phase is visibly starting to deliver through record revenue, reagent pull-through, and cost-optimization moves. The numbers lag the crossing, as the company is still pre-profitability and targeting cash-flow positivity only in 2025.